XML 16 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Interim Statements of Changes in Equity (Unaudited) - USD ($)
$ in Thousands
Ordinary shares [Member]
Additional paid in capital [Member]
Accumulated deficit [Member]
Total
Beginning balance at Dec. 31, 2019 [1] [2] $ 30,117 $ (17,744) $ 12,373
Beginning balance (in shares) at Dec. 31, 2019 [1],[2] 9,274,838      
Share-based compensation [1]   46   46
Net loss for the period [1]     (1,695) (1,695)
Ending balance at Mar. 31, 2020 [1] [2] 30,163 (19,439) 10,724
Ending balance (in shares) at Mar. 31, 2020 [1],[2] 9,274,383      
Beginning balance at Dec. 31, 2019 [1] [2] 30,117 (17,744) 12,373
Beginning balance (in shares) at Dec. 31, 2019 [1],[2] 9,274,838      
Net loss for the period       (4,000)
Ending balance at Sep. 30, 2020 [1] [2] 33,901 (21,744) 12,157
Ending balance (in shares) at Sep. 30, 2020 [1],[2] 9,274,838      
Beginning balance at Mar. 31, 2020 [1] [2] 30,163 (19,439) 10,724
Beginning balance (in shares) at Mar. 31, 2020 [1],[2] 9,274,383      
Share-based compensation [1]   28   28
Exercise of Options [1]   125   125
Issuance of shares, net of issuance costs [1]   3,000   3,000
Net loss for the period [1]     (1,081) (1,081)
Ending balance at Jun. 30, 2020 [1] [2] 33,316 (20,520) 12,796
Ending balance (in shares) at Jun. 30, 2020 [1],[2] 9,274,838      
Share-based compensation [1]   23   23
Exercise of Options [1]   562   562
Net loss for the period [1]     (1,224) (1,224)
Ending balance at Sep. 30, 2020 [1] [2] 33,901 (21,744) 12,157
Ending balance (in shares) at Sep. 30, 2020 [1],[2] 9,274,838      
Beginning balance at Dec. 31, 2020 [3] 34,497 (23,695) 10,802
Beginning balance (in shares) at Dec. 31, 2020 [3] 9,274,838      
Share-based compensation   43   43
Effect of reverse capitalization transaction   2,476   2,476
Effect of reverse capitalization transaction (in shares) 152,299,702      
Issuance of shares and warrants, net of issuance costs   43,547   43,547
Issuance of shares and warrants, net of issuance costs (In shares) 52,385,400      
Net loss for the period     (1,704) (1,704)
Ending balance at Mar. 31, 2021 80,563 (25,399) 55,164
Ending balance (in shares) at Mar. 31, 2021 213,959,940      
Beginning balance at Dec. 31, 2020 [3] 34,497 (23,695) 10,802
Beginning balance (in shares) at Dec. 31, 2020 [3] 9,274,838      
Net loss for the period       (7,442)
Ending balance at Sep. 30, 2021 96,649 (31,137) 65,512
Ending balance (in shares) at Sep. 30, 2021 227,956,060      
Beginning balance at Mar. 31, 2021 80,563 (25,399) 55,164
Beginning balance (in shares) at Mar. 31, 2021 213,959,940      
Share-based compensation   527   527
Issuance of shares and warrants, net of issuance costs   15,118   15,118
Issuance of shares and warrants, net of issuance costs (In shares) 13,996,120      
Net loss for the period     (2,770) (2,770)
Ending balance at Jun. 30, 2021 96,208 (28,169) 68,039
Ending balance (in shares) at Jun. 30, 2021 227,956,060      
Share-based compensation   441   441
Net loss for the period     (2,968) (2,968)
Ending balance at Sep. 30, 2021 $ 96,649 $ (31,137) $ 65,512
Ending balance (in shares) at Sep. 30, 2021 227,956,060      
[1] Number and type of equity instruments reflects the capital of the legal parent (the Company).
[2] Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1B).
[3] Number of shares has been retroactively adjusted to reflect the share reverse split effected on March 16, 2021 (refer to Note 1).